Nasus Pharma (NSRX) Cash & Equivalents (2024 - 2025)
Nasus Pharma (NSRX) posted Cash & Equivalents of $1.2 million for Q4 2025, up 509.36% quarter-over-quarter from $203000.0 in Q2 2025, and up 335.56% year-on-year from $284000.0 in Q4 2024.
Nasus Pharma (NSRX) Cash & Equivalents (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has reported Cash & Equivalents for 2 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- Cash & Equivalents for Q4 2025 came in at $1.2 million, up 335.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.2 million (up 335.56% YoY), and the FY2025 annual result was $1.2 million, up 335.56% from the prior year.
- Cash & Equivalents was $1.2 million for Q4 2025 at Nasus Pharma, up from $203000.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $1.2 million in Q4 2025 and troughed at $203000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 21.69 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Nasus Pharma | 28.20 Mn | 23.91 Mn | - | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Jun 30, 2025 | 232,000.00 |
| Dec 31, 2024 | 284,000.00 |